Collaborative cohort study of an intervention to reduce ventilator-associated pneumonia in the intensive care unit.

Published

Journal Article

OBJECTIVE: To evaluate the impact of a multifaceted intervention on compliance with evidence-based therapies and ventilator-associated pneumonia (VAP) rates. DESIGN: Collaborative cohort before-after study. SETTING: Intensive care units (ICUs) predominantly in Michigan. INTERVENTIONS: We implemented a multifaceted intervention to improve compliance with 5 evidence-based recommendations for mechanically ventilated patients and to prevent VAP. A standardized CDC definition of VAP was used and maintained at each site, and data on the number of VAPs and ventilator-days were obtained from the hospital's infection preventionists. Baseline data were reported and postimplementation data were reported for 30 months. VAP rates (in cases per 1,000 ventilator-days) were calculated as the proportion of ventilator-days per quarter in which patients received all 5 therapies in the ventilator care bundle. Two interventions to improve safety culture and communication were implemented first. RESULTS: One hundred twelve ICUs reporting 3,228 ICU-months and 550,800 ventilator-days were included. The overall median VAP rate decreased from 5.5 cases (mean, 6.9 cases) per 1,000 ventilator-days at baseline to 0 cases (mean, 3.4 cases) at 16-18 months after implementation (P < .001) and 0 cases (mean, 2.4 cases) at 28-30 months after implementation (P < .001). Compared to baseline, VAP rates decreased during all observation periods, with incidence rate ratios of 0.51 (95% confidence interval, 0.41-0.64) at 16-18 months after implementation and 0.29 (95% confidence interval, 0.24-0.34) at 28-30 months after implementation. Compliance with evidence-based therapies increased from 32% at baseline to 75% at 16-18 months after implementation (P < .001) and 84% at 28-30 months after implementation (P < .001). CONCLUSIONS: A multifaceted intervention was associated with an increased use of evidence-based therapies and a substantial (up to 71%) and sustained (up to 2.5 years) decrease in VAP rates.

Full Text

Duke Authors

Cited Authors

  • Berenholtz, SM; Pham, JC; Thompson, DA; Needham, DM; Lubomski, LH; Hyzy, RC; Welsh, R; Cosgrove, SE; Sexton, JB; Colantuoni, E; Watson, SR; Goeschel, CA; Pronovost, PJ

Published Date

  • April 2011

Published In

Volume / Issue

  • 32 / 4

Start / End Page

  • 305 - 314

PubMed ID

  • 21460481

Pubmed Central ID

  • 21460481

Electronic International Standard Serial Number (EISSN)

  • 1559-6834

Digital Object Identifier (DOI)

  • 10.1086/658938

Language

  • eng

Conference Location

  • United States